Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 74 Hodgkin Disease 56 Lymphoma 22 Sarcoma 13 Neoplasm Metastasis 11 Leiomyosarcoma 8 Uveal Melanoma 7 Neoplasms 7 Skin Neoplasms 6 Neuroblastoma 4 Sarcoma, Synovial 3 Recurrence 3 Solitary Fibrous Tumors 2 Sarcoma, Alveolar Soft Part 2 Hematologic Diseases 2 HIV Infections 2 Thyroid Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Skin Diseases 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Melanoma, Cutaneous Malignant 1 Melanoma Neoplasms 1

Interventions

pembrolizumab 3 Paclitaxel 2 relatlimab 1 nintedanib 1 lifileucel 1 dabrafenib 1 Vitamin D 1 Temozolomide 1 Surveys and Questionnaires 1 Opdualag 1 Nivolumab 1 Microarray Analysis 1 Ipilimumab 1 Genetic Testing 1 Gene Expression Profiling 1 Eye Movement Desensitization Reprocessing 1 Electrochemotherapy 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Biopsy 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma, Cutaneous Malignant × Dacarbazine × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡